# Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

> **NCT05964413** · PHASE3 · TERMINATED · sponsor: **InflaRx GmbH** · enrollment: 54 (actual)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **DRUG:** vilobelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05964413
- **Lead sponsor:** InflaRx GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2025-07-11
- **Final completion:** 2025-07-11
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Study stopped for futility
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964413, "Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05964413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*